M
Markus Hoffmann
Researcher at German Primate Center
Publications - 155
Citations - 23747
Markus Hoffmann is an academic researcher from German Primate Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 30, co-authored 103 publications receiving 14853 citations. Previous affiliations of Markus Hoffmann include University of Veterinary Medicine Hanover & University of Veterinary Medicine Vienna.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.
TL;DR: It is reported that the cellular protease furin cleaves the spike protein at the S1/S2 site and that cleavage is essential for S-protein-mediated cell-cell fusion and entry into human lung cells and identifies furin as a potential target for therapeutic intervention.
Journal ArticleDOI
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Markus Hoffmann,Markus Hoffmann,Prerna Arora,Prerna Arora,Rüdiger Groß,Alina Seidel,Bojan F. Hörnich,Alexander S. Hahn,Nadine Krüger,Luise Graichen,Heike Hofmann-Winkler,Amy Kempf,Amy Kempf,Martin Sebastian Winkler,Sebastian R. Schulz,Hans-Martin Jäck,Bernd Jahrsdörfer,Bernd Jahrsdörfer,Hubert Schrezenmeier,Hubert Schrezenmeier,Martin Müller,Alexander Kleger,Jan Münch,Stefan Pöhlmann,Stefan Pöhlmann +24 more
TL;DR: In this article, the authors show that SARS-CoV-2/COVID-19 variants B.1.7 (UK), B.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies.
Posted ContentDOI
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Markus Hoffmann,Hannah Kleine-Weber,Nadine Krueger,Marcel A Mueller,Christian Drosten,Stefan Poehlmann +5 more
TL;DR: The results reveal important commonalities between 2019-nCoV and SARS-coronavirus infection, which might translate into similar transmissibility and disease pathogenesis and identify a target for antiviral intervention.
Journal ArticleDOI
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
Daniel Wrapp,Dorien De Vlieger,Kizzmekia S. Corbett,Gretel M. Torres,Nianshuang Wang,Wander Van Breedam,Kenny Roose,Loes van Schie,Markus Hoffmann,Stefan Pöhlmann,Barney S. Graham,Nico Callewaert,Bert Schepens,Xavier Saelens,Jason S. McLellan +14 more
TL;DR: The isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronav virus outbreaks.